Table 3 Summary of individual treatments utilized over the course of follow-up at MDACC for patients in this series.
From: Malignant head and neck paragangliomas: Is there an optimal treatment strategy?
Treatments, side-effects and responses for patients included in this study | ||||||||
|---|---|---|---|---|---|---|---|---|
Gender | Radiation | Chemotherapy | ||||||
Received | Dose (Gy) | Side Effects | Response | Received | Regimen | Side Effects | Response | |
F | Y | 143 | Skin sloughing | Progression | Y | CCNU, Adriamycin | Alopecia | Progression |
M | N | -- | -- | -- | N | -- | -- | -- |
F | Y | 55 | Otalgia | Progression | N | -- | -- | -- |
M | Y | N/A | N/A | Progression | Y | VP-16, Cisplatin | N/A | Progression |
F | Y | 68 | Mucositis | Progression | Y | DTIC, Adriamycin, Mesna, Ifosfamide | N/A | Progression |
F | Y | N/A | N/A | Progression | Y | CDDP, VP-16 | None | Progression |
F | Y | N/A | N/A | Regression | Y | N/A | N/A | Regression |
M | Y | 90 | N/A | Progression | Y | CVAD | Febrile neutropenia, N/V | Stable |
F | Y | 39 | N/A | N/A | Y | CVAD | N/A | N/A |
M | Y | 60 | None | Progression | Y | Adriamycin, Cytoxan, VP-16, Cisplatin, FTI | None | Progression |
F | N | -- | -- | -- | Y | CVAD | N/A | N/A |
M | Y | N/A | N/A | Progression | N | -- | -- | -- |
F | N | -- | -- | -- | N | -- | -- | -- |
F | Y | N/A | N/A | Stable | N | -- | -- | -- |
F | Y | N/A | N/A | Progression | Y | Taxol, Cytoxan, Adriamycin, DTIC | None | Stable |
F | Y | N/A | N/A | Progression | N | -- | -- | -- |
F | N | -- | -- | -- | N | -- | -- | -- |
F | N | -- | -- | -- | N | -- | -- | -- |
F | Y | N/A | Mucositis | Progression | Y | CVAD | Alopecia | Progression |